Literature DB >> 200171

Growth properties of mecillinam-resistant bacterial variants in urine.

J D Anderson, M A Adams, H M Webster, L Smith.   

Abstract

Resistant variants are often formed when susceptible Enterobacteriaceae are grown in media containing mecillinam. These variants have not yet been detected in patients or identified as a cause of treatment failure in limited clinical trials. Mecillinam-resistant organisms were formed by 5 out of 13 urinary isolates of Enterobacteriaceae incubated in urine containing mecillinam. The mean generation time of these five variants in urine containing therapeutic concentrations of mecillinam was 3.2 times that of normal organisms in antibiotic-free urine. When three of these five resistant variants were subcultured in antibiotic-free urine, the generation time, morphology, and antibiotic susceptibility returned to normal. On antibiotic-free agar medium, all five mecillinam-resistant variants readily reverted to the "susceptible" form and were therefore more likely to be phenotypic rather than genotypic mutants. In a second series of experiments, the flushing effect of the bladder on the clearance of organisms was partly simulated by frequent subculture in urine. Under these conditions, the cell density of cultures of all bacteria remained high during 10 subcultures over 52 h. However, bacterial populations progressively decreased in urine containing mecillinam until none could be detected at 28 h or thereafter. The slow growth rate of mecillinam-resistant variants may explain why detectable numbers of these organisms fail to colonize the urinary tract during treatment. Other factors may reinforce the postulated effect of the reduced growth rate in vivo.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 200171      PMCID: PMC429975          DOI: 10.1128/AAC.12.5.559

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Bacteriology and pharmacokinetics of the new amidino penicillin-mecillinam.

Authors:  J D Williams; J Andrews; M Mitchard; M J Kendall
Journal:  J Antimicrob Chemother       Date:  1976-03       Impact factor: 5.790

2.  The relevance of urine and serum antibacterial activity to the treatment of urinary tract infections.

Authors:  J D Anderson
Journal:  J Antimicrob Chemother       Date:  1976-09       Impact factor: 5.790

3.  Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: in vitro evaluation.

Authors:  L Tybring
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

4.  Studies on the effect of mecillinam upon Micrococcaceae and faecal streptococci under conditions simulating urinary tract infection.

Authors:  J D Anderson; M A Adams; L C Wilson; C A Shepherd
Journal:  J Antimicrob Chemother       Date:  1976-12       Impact factor: 5.790

5.  A laboratory evaluation of a novel (beta-lactam antibiotic mecillinam.

Authors:  D S Reeves; R Wise; M J Bywater
Journal:  J Antimicrob Chemother       Date:  1975-09       Impact factor: 5.790

6.  FL 1039 in bacteriuria following prostatectomy. A double-blind comparison with pivampicillin and placebo.

Authors:  J C Christoffersen; H G Iversen; J Jacobsen; B Korner; H K Petersen; F Rasmussen; L Tybring
Journal:  Scand J Urol Nephrol       Date:  1974

7.  Treatment of recurrent bacteriuria with pivmecillinam (FL 1039).

Authors:  E R Verrier Jones; A W Asscher
Journal:  J Antimicrob Chemother       Date:  1975-06       Impact factor: 5.790

8.  Pharmacokinetic studies with mecillinam and pivmecillinam.

Authors:  K Roholt; B Nielsen
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

9.  FL 1060: a new beta-lactam antibiotic with novel properties.

Authors:  D Greenwood; F O'Grady
Journal:  J Clin Pathol       Date:  1973-01       Impact factor: 3.411

10.  Comparison of the epidemiology of bacterial resistance to mecillinam and ampicillin.

Authors:  J D Anderson; M A Adams; J C Barrington; W N Spence; C A Sheperd
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.